Neuroprotective Agents: Therapeutic Applications & Global Markets 2016-2018 to 2022 - ResearchAndMarkets.com

July 9, 2018

DUBLIN--(BUSINESS WIRE)--Jul 9, 2018--The “Neuroprotective Agents: Therapeutic Applications and Global Markets” report has been added to ResearchAndMarkets.com’s offering.

The scope of this report covers the global market for small molecule drugs, monoclonal antibodies, gene and cell therapies, and other biotechnology products that are approved or being developed for the treatment of neurological disorders.

Therapeutic indications are grouped into four categories: cerebrovascular diseases, neurodegenerative disorders, ophthalmic diseases and traumatic CNS injuries.

Indication subcategories include stroke, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington’s disease, spinal muscular atrophy, epilepsy, glaucoma, age-related macular degeneration, optic neuropathies, diabetic retinopathy and traumatic brain and spinal cord injuries.

The report does not cover the neuroprotective agents that are used for protecting the brain during risky neurosurgeries and other general operations.

Report Highlights

39 tables An overview of the global market for neuroprotective agents and their therapeutic applications Analyses of global market trends, with data from 2016, 2017, and projections of compound annual growth rates (CAGRs) through 2022 Market breakdowns by indication, mechanism of action, and by region Discussion of various neurodegenerative disorders Profiles of key companies in the market, including Bayer Healthcare, Eisai Inc., Glaxosmithkline Plc, Merck Serono S.A., Novartis Ag and Teva Pharmaceutical Industries Ltd.

Key Topics Covered

1 Introduction

2 Summary and Highlights

3 Market and Technology Background

4 Market Breakdown by Technology Type

5 Market Breakdown by Therapeutic Indication

6 Market Breakdown by Region

7 Company Profiles

Companies Mentioned

AB Science S.A. Acucela Inc. Aerie Pharmaceuticals Inc. Allergan Astrazeneca Plc Athersys Inc. Avexis Inc. Bayer Healthcare Biogen Inc. Boehringer Ingelheim Brainstorm Cell Therapeutics Inc. Bristol-Myers Squibb Co. Celgene Corp. Corestem Inc. Covis Pharma Daiichi Sankyo Inc. Eisai Inc. Fortress Biotech Inc. Genervon Biopharmaceuticals Llc Glaxosmithkline Plc GW Pharmaceuticals Plc H. Lundbeck A/S Janssen Pharmaceuticals Inc. Medday Pharmaceuticals Sas Merck Serono S.A. Mitsubishi Pharma Corp. Newron Pharmaceuticals Spa Novartis AG Pfizer Inc. Quark Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc. Reneuron Group Plc Roche Holding AG Sanofi Teva Pharmaceutical Industries Ltd. UCB Pharma S.A. Vertex Pharmaceuticals Inc. VTV Therapeutics Inc. Zogenix Inc.

For more information about this report visit https://www.researchandmarkets.com/research/4sdq9b/neuroprotective?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180709005384/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/09/2018 06:22 AM/DISC: 07/09/2018 06:22 AM


Update hourly